The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time
CHEST · 2026-04 · 169 (4) · 878-879
DOI: 10.1016/j.chest.2025.12.050 ↗Kurz gefasst
Editorial in der Zeitschrift CHEST, 2026-04. Verfasst von Vishisht Mehta. Beteiligte Einrichtung: Comprehensive Cancer Centers of Nevada and the Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV. Electronic address: …. Die Arbeit nennt 9 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Comprehensive Cancer Centers of Nevada and the Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, NV. Electronic address: vishisht.mehta@gmail.com.
Zitieren
APA
Mehta, V. (2026). The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time. CHEST, 169(4), 878-879. https://doi.org/10.1016/j.chest.2025.12.050
Vancouver
Mehta V. The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time. CHEST. 2026;169(4):878-879. doi:10.1016/j.chest.2025.12.050
BibTeX
@article{Mehta2026,
author = {Mehta, Vishisht},
title = {The Second Multicenter Intrapleural Sepsis Trial Dosing Regimen of Intrapleural Enzyme Therapy Remains the Benchmark in Parapneumonic Effusions and Empyema, Even Without Dwell Time},
journal = {CHEST},
year = {2026},
volume = {169},
number = {4},
pages = {878--879},
doi = {10.1016/j.chest.2025.12.050}
}
EUVIMED